CF PharmTech, Inc. disclosed that it repurchased 11,500 H-shares on 12 May 2026, all of which are being held as treasury shares.

• Size and price: The shares were bought on the Hong Kong Stock Exchange at prices ranging from HK$21.62 to HK$21.80, with a volume-weighted average of HK$21.71. Total consideration was approximately HK$0.25 million.

• Capital structure after the transaction: – Issued shares (excluding treasury shares) decreased to 301.50 million. – Treasury shares rose to 719,000. – Total issued shares remained unchanged at 302.22 million. – The buy-back represented 0.0038 % of the company’s issued share capital (excluding treasury shares) prior to the transaction.

• Repurchase mandate utilisation: – The current mandate, approved on 16 December 2025, allows the company to repurchase up to 30.22 million shares. – Cumulative repurchases under this mandate now stand at 719,000 shares, or 0.24 % of the issued shares outstanding on the mandate date.

• Moratorium: Under Hong Kong listing rules, the company may not issue new shares or dispose of treasury shares until 11 June 2026.

The repurchase was authorised by the board and conducted in full compliance with Main Board Rule 10.06 and other applicable regulations, according to Executive Director and Joint Company Secretary Zhu Yuyu.